DKK6.18 -0.1 -1.0%
Last Trade - 26/02/21
| Market Cap | ÂŁ192.0m |
| Enterprise Value | ÂŁ190.6m |
| Revenue | ÂŁ2.60m |
| Position in Universe | 712th / 1874 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.7 | 20.4 | 20.7 | 25.2 | 26.0 | 26.6 | 24.3 | 59.4 | +7.3% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | November 22, 1917 |
| Public Since | January 2, 1985 |
| No. of Shareholders: | 8,478 |
| No. of Employees: | 28 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | OMX Nordic Exchange - Copenhagen |
| Shares in Issue | 266,581,904 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Tuborg Havnevej 15 St, HELLERUP, 2900, Denmark |
| Web | http://www.bioporto.com/ |
| Phone | +45 45 290000 |
| Contact | Christina Thomsen (Investor Relations Manager) |
| Auditors | PricewaterhouseCoopers |
As of 26/02/21, shares in Bioporto A/S are trading at DKK6.18, giving the company a market capitalisation of ÂŁ192.0m. This share price information is delayed by 15 minutes.
Shares in Bioporto A/S are currently trading at DKK6.18 and the price has moved by 0.177k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioporto A/S price has moved by 0.156k% over the past year.
Of the analysts with advisory recommendations for Bioporto A/S, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bioporto A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bioporto A/S is scheduled to issue upcoming financial results on the following dates:
Bioporto A/S does not currently pay a dividend.
Bioporto A/S does not currently pay a dividend.
Bioporto A/S does not currently pay a dividend.
To buy shares in Bioporto A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bioporto A/S are currently trading at DKK6.18, giving the company a market capitalisation of ÂŁ192.0m.
Here are the trading details for Bioporto A/S:
Based on an overall assessment of its quality, value and momentum, Bioporto A/S is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Bioporto A/S are currently priced at DKK6.18. At that level they are trading at 9.87% premium to the analyst consensus target price of 0.00.
Analysts covering Bioporto A/S currently have a consensus Earnings Per Share (EPS) forecast of -0.315 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioporto A/S. Over the past six months, the relative strength of its shares against the market has been 0.170k%. At the current price of DKK6.18, shares in Bioporto A/S are trading at 82.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Bioporto A/S.
Bioporto A/S's management team is headed by:
Here are the top five shareholders of Bioporto A/S based on the size of their shareholding:
